Development by Design Methodology

The key to successful manufacturing of patient-specific cell therapies

Drug Target Review

Your gateway to the drug discovery industry.

Brian Hampson and David Smith of PCT offer an in-depth focus on Stem Cells in the Summer 2017 issue of Drug Target Review.

Beginning with an introduction to the 'unit operation approach' for the cell therapy industry, Brian Hampson and David Smith discuss how a Development by Design (DbD) methodology is the key to successful manufacturing.

In this issue, you'll find:

  • An overview of Development by Design for patient-specific cell therapies (PSCTs)
  • Risks and challenges of providing scalability and sustainability
  • The importance of reducing COGS early on
  • Why planning ahead is crucial to success

To learn more about creating a manufacturing process with Development by Design, fill out the form below.

Access the Issue: